Literature DB >> 1524894

Association between chromosome 11q13 amplification and prognosis of patients with oesophageal carcinomas.

M Mori1, T Tokino, A Yanagisawa, M Kanamori, Y Kato, Y Nakamura.   

Abstract

Ninety pairs of normal and tumour tissue DNAs were isolated from paraffin-embedded blocks of advanced oesophageal carcinoma cases and examined for gene amplification at chromosome 11q13 by dot-blot hybridisation using the int-2 gene as a probe. 22 of 90 carcinomas (24%) showed more than two times amplification. Although no significant correlation was observed between gene amplification and histological type or metastasis to lymph node, a tendency for deeper invasion to be associated with more frequent amplification was observed. In relation to prognosis, patients with amplification had a lower survival rate than those without amplification. This tendency was evident both in the group with well differentiated type carcinoma and in the group which had no metastasis to lymph node. Thus, gene amplification of the int-2 locus may be a useful prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524894     DOI: 10.1016/0959-8049(92)90109-f

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

Review 1.  DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review.

Authors:  Yu Chen; Chu Chen
Journal:  Head Neck       Date:  2008-10       Impact factor: 3.147

2.  Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1.

Authors:  J Adélaide; G Monges; C Dérdérian; J F Seitz; D Birnbaum
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

Review 3.  A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Authors:  J M Findlay; M R Middleton; I Tomlinson
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.